Neurofilament Light Chain Concentration in the Prediction of Treatment Response in Multiple Sclerosis
European Journal of Neurology · 2026
DOI: 10.1111/ene.70505 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2026. Verfasst von Nahid Moradi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Core, Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Neurofilament Proteins, Multiple Sclerosis, Immunologic Factors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
Introduction
Management of multiple sclerosis (MS) revolves around timely initiation of effective disease‐modifying therapy. Here we investigate the additive predictive value of age‐adjusted normalised neurofilament light chain (NfL) concentrations when combined with a clinicodemographic model of treatment response.
Methods
Data were obtained from three sources: the University Hospital Basel, the SET cohort in Prague, and EIMS and IMSE cohorts from Sweden. NfL samples were collected within 90 days of baseline, age‐adjusted and normalised using a reference population. Principal component analysis reduced the dimensionality of clinicodemographic predictors. Cox proportional hazards models estimated cumulative hazards of relapse, 6‐month confirmed disability worsening and 9‐month confirmed disability improvement, with and without NfL. Uno's concordance index compared prediction accuracy across pooled and treatment‐specific models.
Results
The study included 1716 individuals across three therapies: interferon β ( n = 554), fingolimod ( n = 307) and natalizumab ( n = 369). Clinicodemographic characteristics were associated with relapse and disability outcomes. While NfL showed no association in the pooled cohort, in the natalizumab group, higher NfL predicted lower probability of disability improvement (HR = 0.819, 95% CI: 0.814–0.823). Pooled models predicted outcomes with moderate accuracy (relapse: 63.4%, disability worsening: 56.4%, improvement: 67.7%), with minimal contribution from NfL. In treatment‐specific models, NfL‐inclusive accuracy ranged from 51.3%–62.2% (relapse), 54.3%–60.3% (worsening) and 65%–67.9% (improvement), closely matching models without NfL.
Conclusion
In well‐characterised MS patients treated with interferon β, fingolimod or natalizumab, clinicodemographic information provides modest prognostic value; however, NfL adds minimal incremental utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Core, Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.
- Neuroimmunology Centre, Department of Neurology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
- Melbourne School of Psychological Sciences, the University of Melbourne, Australia.
- Neurologic Clinic and Policlinic, MS Centre and Research Centre for Clinical Neuroimmunology and Neuroscience Basel, University of Basel, Basel, Switzerland.
- Clinical Trial Unit, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
- Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
ORCID-Profile: Nahid Moradi, Tomas Uher, Ingrid Kochum
Förderung
- National Health and Medical Research Council
Zitieren
APA
Moradi, N., Sharmin, S., Malpas, C. B., Kuhle, J., Benkert, P., Leppert, D., Havrdová, E. K., Horáková, D., Kleinová, P., Uher, T., Manouchehrinia, A., Hillert, J., Olsson, T., Kochum, I., Taylor, B. V., Barnett, M., Kilpatrick, T. J., Buzzard, K., & Kalincik, T. (2026). Neurofilament Light Chain Concentration in the Prediction of Treatment Response in Multiple Sclerosis. European Journal of Neurology. https://doi.org/10.1111/ene.70505
Vancouver
Moradi N, Sharmin S, Malpas CB, Kuhle J, Benkert P, Leppert D, et al. Neurofilament Light Chain Concentration in the Prediction of Treatment Response in Multiple Sclerosis. European Journal of Neurology. 2026. doi:10.1111/ene.70505
BibTeX
@article{Moradi2026,
author = {Moradi, Nahid and Sharmin, Sifat and Malpas, Charles B and Kuhle, Jens and Benkert, Pascal and Leppert, David and Havrdová, Eva Kubala and Horáková, Dana and Kleinová, Pavlína and Uher, Tomas and Manouchehrinia, Ali and Hillert, Jan and Olsson, Tomas and Kochum, Ingrid and Taylor, Bruce V and Barnett, Michael and Kilpatrick, Trevor J and Buzzard, Katherine and Kalincik, Tomas},
title = {Neurofilament Light Chain Concentration in the Prediction of Treatment Response in Multiple Sclerosis},
journal = {European Journal of Neurology},
year = {2026},
doi = {10.1111/ene.70505}
}
EUVIMED